Blood immune indexes can predict lateral lymph node metastasis of thyroid papillary carcinoma

Objective To explore the clinical significance of blood immune indexes in predicting lateral lymph node metastasis (LLNM) of thyroid papillary carcinoma (PTC). Methods The pathological data and preoperative blood samples of 713 patients that underwent thyroid surgery at affiliated Hangzhou First People’s Hospital Zhejiang University School of Medicine from January 2013 to June 2021 were collected as the model group. The pathological data and preoperative blood samples of 177 patients that underwent thyroid surgery in the same hospital from July 2021 to October 2021 were collected as the external validation group. Univariate and multivariate logistic regression analyses were used to determine the independent risk factors of LLNM in PTC patients. A predictive model for assessing LLNM in PTC patients was established and externally validated using the external data. Results According to univariate and multivariate logistic regression analyses, tumor diameter (P < 0.001, odds ratios (OR): 1.205, 95% confidence interval (CI): 1.162–1.249) and the preoperative systemic immune-inflammation index (SII) (P = 0.032, OR: 1.001, 95% CI: 1.000–1.002) were independent risk factors for distinguishing LLNM in PTC patients. When the Youden index was the highest, the area under the curve (AUC) was 0.860 (P < 0.001, 95% CI: 0.821–0.898). The externally validated AUC was 0.827 (P < 0.001, 95% CI: 0.724–0.929), the specificity was 86.4%, and the sensitivity was 69.6%. The calibration curve and the decision curve indicated that the model had good diagnostic value. Conclusion Blood immune indexes can reflect the occurrence of LLNM and the biological behavior of PTC. The predictive model established in combination with SII and tumor diameter can effectively predict the occurrence of LLNM in PTC patients.

[1]  R. Claus,et al.  Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma , 2021, Cancer Immunology, Immunotherapy.

[2]  Wei Li,et al.  The Efficacy of Different Inflammatory Markers for the Prognosis of Patients with Malignant Tumors , 2021, Journal of inflammation research.

[3]  C. Barbu,et al.  Platelet Activation and Inflammation in Patients with Papillary Thyroid Cancer , 2021, Diagnostics.

[4]  Jiucun Wang,et al.  Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma , 2021, Nature Communications.

[5]  Ping Wang,et al.  The Addition of Peripheral Blood Inflammatory Indexes to Nomogram Improves the Predictive Accuracy of Survival in Limited-Stage Small Cell Lung Cancer Patients , 2021, Frontiers in Oncology.

[6]  H. You,et al.  Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated inflammation , 2021, Experimental & Molecular Medicine.

[7]  Wenzhi Guo,et al.  Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients , 2021, Aging.

[8]  Zeyu Zhang,et al.  The systemic immune-inflammation index-based model is an effective biomarker on predicting central lymph node metastasis in clinically nodal-negative papillary thyroid carcinoma. , 2021, Gland surgery.

[9]  Yue-chu Dai,et al.  T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis , 2021, Diagnostic Pathology.

[10]  Wenyi Zhou,et al.  Risk Factors for Central and Lateral Lymph Node Metastases in Patients With Papillary Thyroid Micro-Carcinoma: Retrospective Analysis on 484 Cases , 2021, Frontiers in Endocrinology.

[11]  F. He,et al.  METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8 mediated neutrophils infiltration. , 2021, Molecular Therapy.

[12]  Kazuhiro Yoshida,et al.  Low intratumoral genetic neutrophil-to-lymphocyte ratio (NLR) is associated with favorable tumor immune microenvironment and with survival in triple negative breast cancer (TNBC). , 2021, American journal of cancer research.

[13]  Pembe Oltulu,et al.  The relationship between types of inflammatory cells located at the micro-environment of papillary thyroid microcarcinoma prognostic factors. , 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[14]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[15]  G. Altan-Bonnet,et al.  Monocyte recruitment and activated inflammation are associated with thyroid carcinogenesis in a mouse model. , 2019, American journal of cancer research.

[16]  Yong Jiang,et al.  Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma , 2019, Clinical and Translational Oncology.

[17]  Z. Özcan,et al.  The Correlation of Clinicopathological Findings and Neutrophil-to- Lymphocyte and Platelet-to-Lymphocyte Ratios in Papillary Thyroid Carcinoma , 2019, Molecular imaging and radionuclide therapy.

[18]  E. J. Ha,et al.  Value of CT added to ultrasonography for the diagnosis of lymph node metastasis in patients with thyroid cancer , 2018, Head & neck.

[19]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[20]  S. Lu,et al.  Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma , 2018, Journal of Endocrinological Investigation.

[21]  Sunita Ghosh,et al.  Autocrine activation of platelet-derived growth factor receptor α in metastatic papillary thyroid cancer. , 2018, Human pathology.

[22]  Seonwoo Kim,et al.  Lateral lymph node metastasis in papillary thyroid carcinoma: A systematic review and meta-analysis for prevalence, risk factors, and location. , 2018, International journal of surgery.

[23]  T. Nakazawa,et al.  Clinicopathological Risk Factors for Distant Metastasis in Differentiated Thyroid Carcinoma: A Meta-analysis , 2018, World Journal of Surgery.

[24]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[25]  Jee Soo Kim,et al.  Patterns, Predictive Factors, and Prognostic Impact of Contralateral Lateral Lymph Node Metastasis in N1b Papillary Thyroid Carcinoma , 2017, Annals of Surgical Oncology.

[26]  F. Tissier,et al.  Recurrence of papillary thyroid carcinoma with lateral cervical node metastases: Predictive factors and operative management. , 2016, Surgery.

[27]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[28]  R. Lai,et al.  Platelet‐derived growth factor receptor‐α promotes lymphatic metastases in papillary thyroid cancer , 2012, The Journal of pathology.

[29]  M. Borrello,et al.  The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies , 2009, Clinical endocrinology.

[30]  F. Schmidt Meta-Analysis , 2008 .